Neutrophil Elastase-Responsive Linkers for Precision Antibody–Drug Conjugates

Antibody-drug conjugates (ADCs) continue to transform oncology, yet premature payload release remains a major source of toxicity. This invention describes a novel class of neutrophil elastase-responsive linker systems that incorporate β-homoamino acids, α-methylamino acids, and polyethylene glycol motifs to improve plasma stability while enabling selective drug release at disease sites. These linker technologies offer a versatile platform for enhancing ADC efficacy, safety, and therapeutic precision.